Table 1 Clinical features of COVID-19 patients in the study and validation cohorts
From: Increased RV:LV ratio on chest CT-angiogram in COVID-19 is a marker of adverse outcomes
Parameters | COVID-19 study cohort (n = 100) | COVID-19 validation cohort (n = 25) | p value |
|---|---|---|---|
Age (years) | 55.1 ± 14.9 | 63.4 ± 12.9 | < 0.01 |
Female, n (%) | 55 (55%) | 8 (32%) | 0.039 |
Symptoms, n (%) | |||
– Shortness of breath | 81 (81%) | 18 (72%) | 0.32 |
– Cough | 80 (80%) | 17 (68%) | 0.20 |
– Fever | 61 (61%) | 14 (56%) | 0.60 |
– Sore-throat | 16 (16%) | 3 (12%) | 0.62 |
Past medical history, n (%) | |||
– Asthma | 21 (21%) | 5 (20%) | 0.91 |
– OSA | 16 (16%) | 8 (32%) | 0.07 |
– HTN | 46 (46%) | 13 (52%) | 0.59 |
– DM | 30 (30%) | 9 (36%) | 0.56 |
– CAD | 14 (14%) | 5 (20%) | 0.45 |
Symptom-onset → COVID-19+ (days) | 5.3 ± 6.3 | 3.2 ± 2.1 | < 0.01 |
COVID-19+ → chest CTA time (days) | 10.3 ± 12.5 | 3.3 ± 3.7 | < 0.01 |
Outcomes, n (%) | |||
– Inpatient | 58 (58%) | 14 (56%) | 0.85 |
– Length of hospital stay (days) | 11.1 ± 9.1 | 10.1 ± 12.7 | 0.78 |
– Supplemental oxygen | 46 (46%) | 11 (44%) | 0.86 |
– ICU admission | 24 (24%) | 3 (12%) | 0.19 |
– Intubation | 19 (19%) | 3 (12%) | 0.41 |
– Death | 10 (10%) | 2 (7%) | 0.76 |
COVID medication, n (%) | |||
– Chloroquine | 6 (6%) | 0 (0%) | 0.21 |
– Convalescent plasma | 5 (5%) | 2 (8%) | 0.13 |
– Remdesivir | 8 (8%) | 0 (0%) | 0.14 |
– Remdesivir + convalescent plasma | 21 (21%) | 9 (36%) | 0.11 |
Laboratory data | |||
D-dimer (mcg/mL) | 1.7 ± 2.9 | 1.1 ± 0.6 | 0.05 |
CRP (mg/dL) | 9.1 ± 8.6 | 14.5 ± 9.6 | 0.08 |
Lactate (mmol/L) | 2.0 ± 1.2 | 1.9 ± 1.3 | 0.84 |
Absolute lymphocytes (/mcL) | 1470 ± 1100 | 1090 ± 650 | 0.03 |
Platelets (K/micro-L) | 221 ± 77 | 201 ± 70 | 0.22 |
Creatinine (mg/dL) | 1.1 ± 1.8 | 1.1 ± 0.3 | 0.83 |